{"title":"非霍奇金淋巴瘤","authors":"James Paterson, Jonathan Lambert","doi":"10.1016/j.mpmed.2025.02.011","DOIUrl":null,"url":null,"abstract":"<div><div>Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the UK and represents a heterogenous group of malignancies. This article gives a brief overview of the current classification of B and T cell NHL, the molecular and cytogenetic abnormalities associated with their pathogenesis, and principles for managing them. Although advances in immuno-chemotherapy and supportive care have resulted in better patient outcomes, many challenges remain, especially for individuals with relapsed and refractory disease.</div></div>","PeriodicalId":74157,"journal":{"name":"Medicine (Abingdon, England : UK ed.)","volume":"53 5","pages":"Pages 319-324"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non-Hodgkin lymphoma\",\"authors\":\"James Paterson, Jonathan Lambert\",\"doi\":\"10.1016/j.mpmed.2025.02.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the UK and represents a heterogenous group of malignancies. This article gives a brief overview of the current classification of B and T cell NHL, the molecular and cytogenetic abnormalities associated with their pathogenesis, and principles for managing them. Although advances in immuno-chemotherapy and supportive care have resulted in better patient outcomes, many challenges remain, especially for individuals with relapsed and refractory disease.</div></div>\",\"PeriodicalId\":74157,\"journal\":{\"name\":\"Medicine (Abingdon, England : UK ed.)\",\"volume\":\"53 5\",\"pages\":\"Pages 319-324\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine (Abingdon, England : UK ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1357303925000453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine (Abingdon, England : UK ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1357303925000453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the UK and represents a heterogenous group of malignancies. This article gives a brief overview of the current classification of B and T cell NHL, the molecular and cytogenetic abnormalities associated with their pathogenesis, and principles for managing them. Although advances in immuno-chemotherapy and supportive care have resulted in better patient outcomes, many challenges remain, especially for individuals with relapsed and refractory disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
